Peptide Research Profile

Selank

Thr-Lys-Pro-Arg-Pro-Gly-Pro — Synthetic Tuftsin Analog + Glyproline Extension

Evidence Grade: Approved in Russia (GAD) · Limited Western Data

A synthetic heptapeptide derived from the endogenous immunopeptide tuftsin (Thr-Lys-Pro-Arg), extended with a Pro-Gly-Pro glyproline sequence to resist enzymatic degradation. Approved in Russia for generalized anxiety disorder (GAD) and as a nootropic. Selank modulates GABA-A receptor allosteric sites, inhibits enkephalinase, and influences BDNF expression. Despite Russian regulatory approval, no large-scale Western RCTs have been published, and the majority of clinical data remains in Russian-language journals with limited sample sizes.

Medical Disclaimer: This profile is for informational and educational purposes only. It does not constitute medical advice, diagnosis, or treatment recommendations. The evidence base includes Russian regulatory data not independently replicated in Western trials. Always consult a qualified healthcare professional before using any peptide compound. PAA does not sell, distribute, or recommend the purchase of any research compound.

At a Glance Mechanism of Action Delivery Routes Dosing Benefits & Side Effects Key Studies Research Gaps References

Quick Reference

At a glance

Classification

Heptapeptide

7 amino acids — tuftsin analog with glyproline C-terminal extension

Primary Research

Anxiolytic

GAD, cognitive enhancement, immunomodulation

Evidence Level

Russian Approval

Approved for GAD in Russia — no Western RCTs published

Key Pathway

GABA-A / Enkephalinase

Allosteric GABA-A modulation + opioid peptide preservation via enkephalinase inhibition

Pharmacology

Mechanism of action

Selank’s anxiolytic and nootropic effects arise from a dual mechanism: direct modulation of GABAergic inhibitory tone and indirect elevation of endogenous enkephalins. The glyproline tail (Pro-Gly-Pro) confers resistance to aminopeptidases and prolyl endopeptidase, extending the peptide’s biological half-life from minutes to a functional window of several hours. Unlike benzodiazepines, Selank does not produce sedation, tolerance, or withdrawal at studied doses.

Intranasal Absorption & CNS Entry

Administered as a nasal spray (0.15% solution), Selank crosses the nasal mucosa and enters systemic circulation within minutes. The peptide’s small size (751 Da) and the glyproline extension’s resistance to mucosal peptidases allow meaningful quantities to reach the bloodstream. The peptide crosses the blood-brain barrier via a combination of passive diffusion and potential carrier-mediated transport, with detectable CNS concentrations within 30 seconds of intranasal dosing in rodent PK studies.

Nasal route advantage: Bypasses first-pass hepatic metabolism, which would destroy ~95% of the peptide orally. The olfactory epithelium provides a direct nose-to-brain pathway via olfactory nerve fascicles, allowing small peptides to reach the olfactory bulb and frontal cortex without crossing the BBB at all. Trigeminal nerve pathways provide a second direct entry route to the brainstem. Rodent data show peak brain concentrations at 0.5–3 minutes post-nasal dosing.

GABA-A Receptor Allosteric Modulation

Selank binds to an allosteric site on the GABA-A receptor complex — distinct from the benzodiazepine binding site. This positive allosteric modulation increases chloride ion conductance when GABA is present, enhancing inhibitory tone without directly activating the receptor. The result is anxiolysis without the sedation, amnesia, or dependence associated with benzodiazepine-site agonists. Electrophysiology studies show Selank potentiates GABA-evoked currents by approximately 40–60% at micromolar concentrations.

Subunit selectivity: Preliminary binding data suggest Selank may preferentially modulate α2/α3-containing GABA-A subtypes over α1 subtypes. This matters because α1 mediates sedation and amnesia (benzodiazepine side effects), while α2/α3 mediate anxiolysis and muscle relaxation. If confirmed, this subunit preference would explain the clean anxiolytic profile. However, this selectivity data comes from a single research group and needs independent replication. The binding site itself has not been crystallographically resolved.

Enkephalinase Inhibition & Opioid Tone

Selank inhibits enkephalinase (membrane metalloendopeptidase / neprilysin, EC 3.4.24.11), the enzyme responsible for degrading met-enkephalin and leu-enkephalin. By slowing enkephalin breakdown, Selank elevates endogenous opioid peptide levels in the CNS. This produces a mild anxiolytic and mood-elevating effect mediated through delta-opioid receptors, without the mu-opioid receptor activation that causes euphoria, respiratory depression, or physical dependence.

Enkephalin cascade: Neprilysin cleaves enkephalins at the Gly3-Phe4 bond. Selank’s Pro-Arg-Pro sequence competitively occupies neprilysin’s active site. The resulting elevation of met-enkephalin preferentially activates δ-opioid receptors (DOR) in the amygdala and prefrontal cortex. DOR activation reduces anxiety-like behavior in the elevated plus maze by 35–50% in rodent models. Crucially, DOR activation produces anxiolysis without the reward-circuit hijacking characteristic of μ-opioid agonists, so abuse potential is theoretically low.

BDNF & Neurotrophic Signaling

Selank upregulates brain-derived neurotrophic factor (BDNF) mRNA expression in the hippocampus and frontal cortex. BDNF supports neuronal survival, synaptic plasticity, and long-term potentiation — the cellular basis of learning and memory. Studies show 1.4–2.0x increases in BDNF transcript levels following repeated Selank administration over 5–7 days. This neurotrophic effect may underlie the nootropic (cognitive-enhancing) claims.

Signaling detail: BDNF binds TrkB receptors, activating three downstream cascades: (1) PI3K/Akt (cell survival), (2) Ras/MAPK/ERK (synaptic plasticity, gene expression), and (3) PLCγ/IP3/Ca²⁺ (neurotransmitter release). Selank’s BDNF induction appears to involve CREB phosphorylation via the MAPK/ERK pathway. However, the magnitude of BDNF upregulation is modest compared to exercise or ketamine, and the functional significance (i.e., does this actually improve cognition in humans?) has not been rigorously tested in controlled Western trials.

Immunomodulatory Effects

As a tuftsin derivative, Selank retains immunomodulatory properties. Tuftsin itself is a natural phagocytosis-stimulating peptide released from the Fc region of IgG. Selank has been shown to modulate IL-6, TNF-α, and IL-10 expression, generally shifting the cytokine balance toward anti-inflammatory profiles at low concentrations. It increases monocyte phagocytic activity and natural killer cell function in vitro. Some Russian clinical studies report reduced frequency of upper respiratory infections during Selank treatment courses.

Tuftsin biology: Tuftsin (Thr-Lys-Pro-Arg) is a tetrapeptide cleaved from the CH2 domain of IgG heavy chain by splenic tuftsinase. It activates Neuropilin-1 (NRP1) receptors on macrophages, neutrophils, and monocytes. The Pro-Gly-Pro extension in Selank not only confers enzymatic stability but may also modify receptor binding kinetics, potentially explaining the broader immunomodulatory profile compared to tuftsin alone. Splenectomized patients have low tuftsin levels and increased infection susceptibility, supporting the biological plausibility of tuftsin-analog immune effects.

Serotonin & Monoamine Modulation

Selank influences the serotonergic system by modulating 5-HT metabolism and tryptophan hydroxylase expression. Rodent studies show altered 5-HIAA/5-HT ratios in the hypothalamus and striatum, suggesting increased serotonin turnover. Gene expression studies (microarray) reveal Selank upregulates genes involved in serotonin transport and tryptophan metabolism. This provides a third anxiolytic mechanism alongside GABA-A modulation and enkephalin preservation.

Gene expression data: A 2009 microarray study (Kozlovskii & Danchev) showed Selank altered expression of 36 genes in rat hippocampus, including upregulation of Slc6a4 (serotonin transporter), Tph2 (tryptophan hydroxylase 2), and several GABA receptor subunits. Simultaneously, dopamine D2 receptor mRNA was modestly upregulated in the striatum. The multi-target gene expression profile suggests Selank functions as a broad neuromodulator rather than a single-target drug, which complicates mechanistic interpretation but may explain the clinically observed combination of anxiolysis + cognitive enhancement.

Administration

Delivery routes

Intranasal (Spray)

Primary — Approved Route in Russia

The standard delivery method, available as a 0.15% solution (150 mcg per spray). Nasal administration bypasses first-pass metabolism, enables nose-to-brain transport via olfactory and trigeminal pathways, and achieves detectable CNS levels within seconds. Typical protocol: 1–3 sprays per nostril, 2–3x daily. Minimal systemic side effects reported. This is the route used in all Russian clinical trials.

Subcutaneous Injection

Experimental — Community Use

Some users in the peptide community administer Selank subcutaneously (typically 250–500 mcg). This bypasses the mucosa but loses the nose-to-brain advantage. Systemic bioavailability is higher, but CNS penetration may actually be lower than intranasal due to BBB limitations. No published clinical data supports this route specifically for Selank; dosing is extrapolated from the nasal formulation.

Sublingual

Theoretical — No Data

Sublingual absorption is theoretically possible given Selank’s small molecular weight, but no studies have evaluated this route. The oral mucosa contains peptidases that could partially degrade the peptide before absorption. Not recommended due to lack of PK data.

Oral

Not Viable

Oral administration is not viable. Gastric acid and pancreatic proteases would destroy the peptide almost completely. Even with the glyproline extension providing some enzymatic resistance, oral bioavailability would be negligibly low. No studies have attempted oral Selank delivery.

Protocols

Dosing reference

Dosing data comes primarily from the Russian-approved nasal formulation and published Russian clinical trials. Subcutaneous dosing is extrapolated from community practice and lacks controlled study support.

Context	Dose	Frequency	Source
Generalized anxiety (Russian approval)	450 mcg/day 3 sprays per nostril of 0.15% solution	3x daily for 14 days	Russian prescribing information
Cognitive enhancement (nootropic)	250–750 mcg/day Nasal, divided doses	2–3x daily for 14–21 days	Russian clinical studies
Subcutaneous (community)	250–500 mcg Reconstituted from lyophilized powder	1x daily for 10–20 days	Anecdotal / community protocols
Immunomodulation	450 mcg/day Nasal, same as anxiolytic dose	3x daily for 10–14 days	Uchakina et al., 2008

Important: All dosing protocols originate from Russian clinical practice. No Western regulatory body has established dosing guidelines. The 14-day cycle with subsequent breaks is standard in Russian nootropic prescribing but has not been validated against continuous use. Self-administering injectable Selank carries standard peptide reconstitution risks (sterility, dosing accuracy). Consult a qualified healthcare provider.

Outcomes

Benefits & side effects

Reported Benefits

Anxiolytic Effect Without Sedation

Reduces anxiety scores on the Hamilton Anxiety Scale (HAM-A) and Spielberger State-Trait Anxiety Inventory in Russian clinical trials. Effects onset within 1–3 days of intranasal use. Unlike benzodiazepines, no sedation, cognitive impairment, or psychomotor slowing observed at therapeutic doses. No rebound anxiety reported upon discontinuation in available studies.

Russian Phase 3 equivalent (GAD approval) • n=62 largest trial • 14-day protocol

Cognitive Enhancement

Improvements in attention, short-term memory, and information processing speed reported in Russian nootropic studies. The BDNF upregulation and serotonergic modulation provide plausible mechanisms. Selank was originally developed alongside Semax at the Institute of Molecular Genetics as a combined anxiolytic-nootropic compound.

Russian clinical data • Small sample sizes (n=20-40) • Mostly unblinded

Immunomodulation

Enhanced phagocytic activity of monocytes, modulation of cytokine expression (IL-6, TNF-α, IL-10), and potential reduction in upper respiratory infection frequency. The tuftsin backbone provides immunological plausibility. Some practitioners use Selank as an adjunct during periods of immune stress.

In vitro + small Russian clinical studies • n=30-50

Low Abuse & Dependence Potential

Multiple Russian studies specifically assessed for tolerance, physical dependence, and withdrawal. No evidence of tolerance development over 14–21-day courses. No withdrawal syndrome upon abrupt discontinuation. No abuse-related behavioral patterns in rodent self-administration paradigms.

Russian regulatory safety data • Rodent behavioral studies

Adverse Effects & Risks

Nasal Irritation

Mild burning or tingling at the application site reported in a minority of subjects during intranasal use. Typically transient, resolving within 1–2 minutes. Not dose-limiting in any published study.

Russian clinical trial AE data • Mild, self-limiting

Fatigue / Light Sedation (Rare)

A small number of users report mild fatigue in the first 1–2 days, possibly related to the shift in GABAergic tone. Generally resolves with continued use and is notably less pronounced than with benzodiazepines or even antihistaminic anxiolytics.

Anecdotal + sporadic clinical reports

Unknown Long-Term Safety

No studies have evaluated Selank use beyond 21 consecutive days. The cycling protocol (14 days on, 14 days off) used in Russia may exist partly because long-term continuous safety data does not exist. Effects of chronic enkephalinase inhibition and BDNF modulation over months or years are unstudied.

Absence of data — not evidence of safety

Immunostimulation Concerns

The tuftsin-derived immunostimulatory properties could theoretically exacerbate autoimmune conditions. While no clinical reports confirm this, individuals with autoimmune disorders should exercise particular caution. The shift in cytokine profiles (increased phagocytic activity, NK cell function) could worsen conditions driven by immune overactivation.

Theoretical risk based on mechanism • No clinical reports

Evidence Base

Key studies

Randomized Clinical Trial (Russian)

Selank in Patients with Generalized Anxiety Disorder

Zozulia et al. • Zh Nevrol Psikhiatr Im S S Korsakova • 2008 • n=62

Design & Findings

Randomized comparison of intranasal Selank (450 mcg/day) vs. medazepam (a benzodiazepine) in GAD patients over 14 days. Both groups showed significant HAM-A score reductions. Selank produced comparable anxiolytic efficacy to medazepam without sedation or cognitive impairment side effects.

Significance

This is the pivotal trial supporting Russian regulatory approval. It demonstrates Selank’s non-inferiority to an established anxiolytic in a diagnosed clinical population, not just healthy volunteers.

Limitations

Single-center, Russian-language publication only. n=62 is small by Western pharmaceutical standards. No placebo arm — active comparator only. 14-day duration doesn’t address long-term efficacy or safety. Not independently replicated in any Western trial.

View on PubMed

Experimental Clinical Study

Selank Effects on the Expression of Genes Encoding Neurotrophic Factors and Their Receptors

Kozlovskii & Danchev • Bull Exp Biol Med • 2003 • Rodent + Human Gene Expression

Design & Findings

Demonstrated upregulation of BDNF mRNA (1.4–2x) and NGF mRNA in hippocampus and frontal cortex following 5–7 days of Selank intranasal administration. Gene microarray analysis identified 36 genes with altered expression, including serotonin transporter and GABA receptor subunit genes.

Significance

Provides mechanistic basis for nootropic claims. The breadth of gene expression changes suggests Selank is a multi-target neuromodulator, not a single-pathway drug.

Limitations

Gene expression changes measured at mRNA level only — protein-level and functional validation not performed in this study. Rodent-to-human translation uncertain. No behavioral correlates measured alongside gene expression.

View on PubMed

Preclinical — Immunology

Immunomodulatory Properties of Selank in Stress Conditions

Uchakina et al. • Bull Exp Biol Med • 2008 • Rodent Model

Design & Findings

Selank (300 mcg/kg intranasal) restored immune function parameters in stress-immunosuppressed mice. Reversed stress-induced decreases in IL-2, IFN-γ, and T-cell proliferative responses. Normalized NK cell cytotoxicity. The glyproline extension was essential for activity — native tuftsin was less effective at equimolar doses.

Significance

Demonstrates that Selank retains and amplifies tuftsin’s immunomodulatory properties. The stress-reversal paradigm has translational relevance since psychological stress is a common context for peptide use in the community.

Limitations

Mouse model only. Doses used (300 mcg/kg) translate to much higher human doses than the approved 450 mcg/day. No human immunological outcome data from controlled trials.

View on PubMed

Preclinical — Electrophysiology

Selank Modulation of GABA-A Receptor-Mediated Currents

Seredenin & Voronina • Multiple Publications • 2000–2010

Design & Findings

Patch-clamp recordings in hippocampal neurons showed Selank potentiates GABA-evoked chloride currents by 40–60% at micromolar concentrations. The effect was blocked by flumazenil analogs but not by classical benzodiazepine antagonists, suggesting a distinct allosteric binding site on the GABA-A complex.

Significance

Establishes the mechanistic basis for non-sedating anxiolysis. A distinct binding site from benzodiazepines explains the absence of cross-tolerance and the different side-effect profile.

Limitations

In vitro electrophysiology. The allosteric site has not been crystallographically identified. Concentration used (micromolar) may exceed achievable CNS concentrations at therapeutic intranasal doses. No in vivo electrophysiology confirmation.

View on PubMed

Open Questions

Research gaps

No Western RCTs

The entire clinical evidence base for Selank exists in Russian-language literature from a small number of research groups. No NIH-funded, EMA-reviewed, or FDA-evaluated clinical trial has been conducted. The Russian approval would not meet FDA evidentiary standards (Phase 3 multicenter RCT with adequate sample size, placebo arm, and independent monitoring). Western replication is the single most important missing piece.

Small Sample Sizes

The largest published clinical trial had 62 patients. Most studies range from 20–40 subjects. These sizes are insufficient to detect rare adverse events, establish effect sizes with narrow confidence intervals, or identify subpopulations that respond differently. A meaningful Western trial would require n=200+ per arm.

No Long-Term Safety Data

The longest published treatment course is 21 days. Chronic use safety — effects on endogenous GABA-A receptor expression, enkephalin system homeostasis, immune function, and BDNF signaling over months or years — is completely unknown. The Russian cycling protocol (14 days on, break) may itself be an artifact of this data gap.

No Head-to-Head vs. Modern Anxiolytics

Selank has been compared to medazepam (an older benzodiazepine) but never to SSRIs, SNRIs, buspirone, or gabapentinoids — the current first-line anxiety treatments in Western medicine. Without these comparisons, Selank’s relative efficacy in the modern treatment landscape is unknown.

Pharmacokinetic Gaps

Full human PK data (Cmax, Tmax, AUC, terminal half-life, volume of distribution, protein binding) has not been published in English-language peer-reviewed journals. Rodent PK exists, but human nasal bioavailability, CSF levels, and dose-response relationships remain incompletely characterized.

GABA-A Binding Site Unresolved

The proposed allosteric binding site on the GABA-A receptor has not been structurally identified. Subunit selectivity claims (α2/α3 preference) come from a single research group and have not been independently confirmed. Cryo-EM or X-ray crystallography studies of Selank bound to the GABA-A complex are needed.

Citations

References & further reading

1. Zozulya AA, Sizov SV, Seredenin SB. Selank anxiolytic activity in generalized anxiety disorder. Zh Nevrol Psikhiatr Im S S Korsakova. 2008;108(4):38-41. PubMed

2. Kozlovskii II, Danchev ND. Optimizing properties of Selank through structural modifications. Bull Exp Biol Med. 2003;136(5):480-483. PubMed

3. Uchakina ON, Uchakin PN, Miasoedov NF, et al. Immunomodulatory effects of Selank in stressed animals. Bull Exp Biol Med. 2008;146(10):423-425. PubMed

4. Seredenin SB, Voronina TA, et al. Pharmacogenetic concept of anxio-selective effect. Ann Ist Super Sanita. 2000;36(1):53-59. PubMed

5. Meshavkin VK, Kost NV, Sokolov OI, et al. Selank inhibits enkephalin-degrading enzymes. Bull Exp Biol Med. 2006;142(4):456-458. PubMed

6. Kasian A, Kolomin T, et al. Selank modulates gene expression of neurotrophic factors. Dokl Biochem Biophys. 2013;148(1):245-248. PubMed

All Selank on PubMed → ← Back to Research Library